Allergan Australia

23 PBAC submissions on file, active 2005–2023. 70% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Botulinum toxin type a
  Neurology · Recommended with restriction · 2019—
• Botulinum toxin type a purified neurotoxin complex
  Neurology · Recommended with restriction · 2019—
• Dexamethasone
  Ophthalmology · Not recommended · 2018—
• Atogepant
  Neurology · Recommended with restriction · 2023—
• Bimatoprost with timolol maleate
  Ophthalmology · Recommended with restriction · 2009—
• Carmellose sodium with glycerol and hyaluronic acid
  Ophthalmology · Recommended with restriction · 2023—

Therapy area mix

Activity by year

2005 (1) · 2006 (1) · 2008 (3) · 2009 (1) · 2010 (1) · 2011 (1) · 2012 (2) · 2013 (2) · 2015 (1) · 2016 (1) · 2017 (2) · 2018 (3) · 2019 (2) · 2023 (2)

Rejection patterns

Across 7 Not recommended decisions on file.

• 2×high and uncertain cost-effectiveness
• 1×Unmet clinical need not adequately justified
• 1×inferior efficacy and safety compared to VEGF inhibitors
• 1×limited clinical place in treatment-failure population
• 1×unclear clinical rationale for 'unsuitable' population (patient preference/logistical reasons)